retatrutide triple agonist glp-1 gip glucagon phase 2 obesity vs Survodutide: vs Dual Comparison for and MASH - Which Is Better? | PPW I am extremely excited about

Read the full app note: To view or add a comment, sign in 790 followers

The GLP-1 market growth is driven by advancements in drug formulations, particularly the development of oral and long-acting therapies

[DOI] [PubMed] [Google Scholar] 433.Quoyer J., Longuet C., Broca C., Linck N., Costes S., Varin E

The post hoc analysis of patients only from the PIONEER 6 (evaluating oral semaglutide) and SUSTAIN 6 (evaluating sc semaglutide) studies found a 23.8% reduction in MACEs associated with semaglutide treatment (HR 0.76, 95% CI 0.620.92), especially in the prevention of nonfatal stroke (HR 0.65, 95% CI 0.430.97) [62]

Blood fats (triglycerides) fell by around 40%

We encourage individuals interested in these treatment options to schedule a consultation with our experienced team to determine the most suitable strategy based on their medical history and weight loss objectives